Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.61
Nov 16 • 3:59 PM ET Dollar change-0.60 Percentage change(-14.25%)
Aftermarket Close
3.61
Aftermarket • 5:00 PM ET Dollar change0.00 Percentage change(0.00%)
Today, 4:02 PMNo clear catalyst identified for Relmada 14 percent drop in Monday regular session
Index
RUT
Market Cap
385.17M
Enterprise Value
183.05M
Income
-65.70M
Sales
0.00M
Book/sh
1.82
Cash/sh
1.89
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
17
IPO
Jun 20, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
1.99
P/C
1.91
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
26.37
Current Ratio
26.37
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.75
EPS next Y
-0.75
EPS next Q
-0.12
EPS this Y
61.38%
EPS next Y
-33.48%
EPS next 5Y
17.98%
EPS past 3/5Y
35.03% 17.54%
Sales past 3/5Y
- -
EPS Y/Y TTM
58.30%
Sales Y/Y TTM
-
EPS Q/Q
59.44%
Sales Q/Q
-
Insider Own
13.01%
Insider Trans
2.97%
Inst Own
90.65%
Inst Trans
14.26%
ROA
-59.68%
ROE
-64.66%
ROIC
-33.91%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-3.36%
SMA50
-3.77%
SMA200
-32.74%
Trades
Shs Outstand
106.69M
Shs Float
92.81M
52W High
8.00 -54.88%
52W Low
3.07 17.59%
Volatility
10.19% 8.42%
ATR (14)
0.36
RSI (14)
45.69
Beta
0.56
Rel Volume
1.79
Avg Volume
1.35M
Volume
2,417,615
Perf Week
-12.80%
Perf Month
16.45%
Perf Quarter
-25.57%
Perf Half Y
-43.06%
Perf YTD
-25.26%
Perf Year
-8.61%
Perf 3Y
22.37%
Perf 5Y
-83.49%
Perf 10Y
0.28%
Prev Close
4.21
Price
3.61
Change %
-14.25%
Consensus
Strong Buy
Avg. Price Target
$10.75
Implied Upside
+197.8%
Analysts11incl. previous ratings
Rating Distribution7 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jun 18, 2026Initiated
HH.C. Wainwright
Buy$12+232.4%
Mar 24, 2026Initiated
PPiper Sandler
Overweight$12+232.4%
Jan 23, 2026Resumed
LLeerink Partners
Outperform$8+121.6%
Dec 22, 2025Initiated
JEF logoJJefferies
Buy$69+1,811.4%
Nov 19, 2025Upgrade
MFG logoMMizuho
Neutral → Outperform$10+177.0%
Dec 05, 2024Downgrade
MFG logoMMizuho
Outperform → Neutral$23 → $1-72.3%
Sep 17, 2024Upgrade
JEF logoJJefferies
Hold → Buy$3.50 → $13+260.1%
Jun 05, 2024Downgrade
GS logoGGoldman
Neutral → Sell$3 → $2-44.6%
Oct 14, 2022Downgrade
TFC logoTTruist
Buy → Hold$90 → $10+177.0%
Oct 14, 2022Downgrade
GGuggenheim
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shenouda MagedChief Financial OfficerSep 09 '26Buy4.20120,200504,840920,200Sep 11 07:30 AM
Shenouda MagedChief Financial OfficerSep 10 '26Buy4.2579,800339,1501,000,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerSep 09 '26Buy4.18100,000418,0001,400,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerSep 10 '26Buy4.10100,000410,0001,500,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerDec 15 '25Buy4.1227,500113,3001,300,000Dec 16 09:30 AM
Shenouda MagedChief Financial OfficerDec 15 '25Buy4.1211,66548,060800,000Dec 16 09:30 AM
Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Pharm.D.Dr. Sergio Traversa M.B.A.
R.Ph.Mr. Maged S. Shenouda M.B.A.
COO & DirectorMr. Paul E. Kelly M.B.A.
M.B.A.Mr. Charles S. Ence CPA
VP & Head of Clinical OperationsMs. Gina DiGuglielmo